Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma

Xiao Li, Fei Qin, Li Yang, Liqian Mo, Lei Li, Lianbing Hou Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China Abstract: Targeted nanoparticle (NP) delivery vehicles are emerging technologies, the full potential of which has yet t...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Li X, Qin F, Yang L, Mo LQ, Li L, Hou LB
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/aa8d9d549e4e4be59f740e0f4322d859
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:aa8d9d549e4e4be59f740e0f4322d859
record_format	dspace
spelling	oai:doaj.org-article:aa8d9d549e4e4be59f740e0f4322d8592021-12-02T06:37:58ZSulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma1178-2013https://doaj.org/article/aa8d9d549e4e4be59f740e0f4322d8592014-08-01T00:00:00Zhttp://www.dovepress.com/sulfatide-containing-lipid-perfluorooctylbromide-nanoparticles-as-pacl-peer-reviewed-article-IJNhttps://doaj.org/toc/1178-2013 Xiao Li, Fei Qin, Li Yang, Liqian Mo, Lei Li, Lianbing Hou Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China Abstract: Targeted nanoparticle (NP) delivery vehicles are emerging technologies, the full potential of which has yet to be realized. Sulfatide is known to bind to extracellular matrix glycoproteins that are highly expressed in breast tumors. In this study, we report for the first time the combination of sulfatide and lipid perfluorooctylbromide NPs as a targeted breast cancer delivery vehicle for paclitaxel (PTX). PTX-sulfatide-containing lipid perfluorooctylbromide NPs (PTX-SNPs) were prepared using the emulsion/solvent evaporation method. PTX-SNPs exhibited a spherical shape, small particle size, high encapsulation efficiency, and a biphasic release in phosphate-buffered solution. The cytotoxicity study and cell apoptosis assay revealed that blank sulfatide-containing lipid perfluorooctylbromide NPs (SNPs) had no cytotoxicity, whereas PTX-SNPs had greater EMT6 cytotoxicity levels than PTX-lipid perfluorooctylbromide NPs (PTX-NPs) and free PTX. An in vitro cellular uptake study revealed that SNPs can deliver greater amounts of drug with more efficient and immediate access to intracellular targets. In vivo biodistribution measured using high-performance liquid chromatography confirmed that the PTX-SNPs can target breast tumor tissues to increase the accumulation of PTX in these tissues. The in vivo tumor inhibition ability of PTX-SNPs was remarkably higher than PTX-NPs and free PTX. Furthermore, toxicity studies suggested that the blank SNPs had no systemic toxicity. All results suggested that SNPs may serve as efficient PTX delivery vehicles targeting breast carcinoma. Keywords: perfluorooctylbromide nanoparticles, paclitaxel, drug delivery, targeting, antitumor efficacyLi XQin FYang LMo LQLi LHou LBDove Medical PressarticleMedicine (General)R5-920ENInternational Journal of Nanomedicine, Vol 2014, Iss Issue 1, Pp 3971-3985 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Li X Qin F Yang L Mo LQ Li L Hou LB Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma
description	Xiao Li, Fei Qin, Li Yang, Liqian Mo, Lei Li, Lianbing Hou Department of Pharmacy, Nanfang Hospital, Southern Medical University, Guangzhou, People’s Republic of China Abstract: Targeted nanoparticle (NP) delivery vehicles are emerging technologies, the full potential of which has yet to be realized. Sulfatide is known to bind to extracellular matrix glycoproteins that are highly expressed in breast tumors. In this study, we report for the first time the combination of sulfatide and lipid perfluorooctylbromide NPs as a targeted breast cancer delivery vehicle for paclitaxel (PTX). PTX-sulfatide-containing lipid perfluorooctylbromide NPs (PTX-SNPs) were prepared using the emulsion/solvent evaporation method. PTX-SNPs exhibited a spherical shape, small particle size, high encapsulation efficiency, and a biphasic release in phosphate-buffered solution. The cytotoxicity study and cell apoptosis assay revealed that blank sulfatide-containing lipid perfluorooctylbromide NPs (SNPs) had no cytotoxicity, whereas PTX-SNPs had greater EMT6 cytotoxicity levels than PTX-lipid perfluorooctylbromide NPs (PTX-NPs) and free PTX. An in vitro cellular uptake study revealed that SNPs can deliver greater amounts of drug with more efficient and immediate access to intracellular targets. In vivo biodistribution measured using high-performance liquid chromatography confirmed that the PTX-SNPs can target breast tumor tissues to increase the accumulation of PTX in these tissues. The in vivo tumor inhibition ability of PTX-SNPs was remarkably higher than PTX-NPs and free PTX. Furthermore, toxicity studies suggested that the blank SNPs had no systemic toxicity. All results suggested that SNPs may serve as efficient PTX delivery vehicles targeting breast carcinoma. Keywords: perfluorooctylbromide nanoparticles, paclitaxel, drug delivery, targeting, antitumor efficacy
format	article
author	Li X Qin F Yang L Mo LQ Li L Hou LB
author_facet	Li X Qin F Yang L Mo LQ Li L Hou LB
author_sort	Li X
title	Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma
title_short	Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma
title_full	Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma
title_fullStr	Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma
title_full_unstemmed	Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma
title_sort	sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/aa8d9d549e4e4be59f740e0f4322d859
work_keys_str_mv	AT lix sulfatidecontaininglipidperfluorooctylbromidenanoparticlesaspaclitaxelvehiclestargetingbreastcarcinoma AT qinf sulfatidecontaininglipidperfluorooctylbromidenanoparticlesaspaclitaxelvehiclestargetingbreastcarcinoma AT yangl sulfatidecontaininglipidperfluorooctylbromidenanoparticlesaspaclitaxelvehiclestargetingbreastcarcinoma AT molq sulfatidecontaininglipidperfluorooctylbromidenanoparticlesaspaclitaxelvehiclestargetingbreastcarcinoma AT lil sulfatidecontaininglipidperfluorooctylbromidenanoparticlesaspaclitaxelvehiclestargetingbreastcarcinoma AT houlb sulfatidecontaininglipidperfluorooctylbromidenanoparticlesaspaclitaxelvehiclestargetingbreastcarcinoma
_version_	1718399832637308928

Sulfatide-containing lipid perfluorooctylbromide nanoparticles as paclitaxel vehicles targeting breast carcinoma

Ejemplares similares